Small to mid-sized research oriented pharmaceutical and biotech companies deploying PK Accelerator will be able to take advantage of the operational efficiencies Pharsight's enterprise and desktop software packages were designed to deliver. Adopting PK Accelerator will allow small to mid-sized organizations to deploy Pharsight's "best practices" solution for end-to-end pharmacokinetic analysis and validatable CFR 21 part 11 reporting in as little as 90 days. Pharsight Corporation, a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, recently announced that it will be launching PK Accelerator (PKA), a system of bundled software coupled with a rapid deployment service provided at a fixed price and fixed scope.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |